此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估法国转移性激素敏感性前列腺癌参与者对阿帕鲁胺用药依从性的研究 (OBSAPA)

2026年11月2日 更新者:Janssen Cilag S.A.S.

法国一项观察性前瞻性研究:法国转移性激素敏感性前列腺癌(mHSPC)患者对阿帕鲁胺的依从性

This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior of metastatic hormone-sensitive prostate cancer (mHSPC) participants treated with apalutamide during the first year of continued treatment.

研究概览

研究类型

观察性的

注册 (估计的)

540

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Caen、法国、14076
        • 招聘中
        • Centre Francois Baclesse

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

取样方法

非概率样本

研究人群

Adult male (according to their chromosomal composition at birth) participants with confirmed diagnosis of mHSPC will be enrolled at the time of initiation of treatment with apalutamide.

描述

Inclusion criteria:

  • Male (based on chromosomal composition at birth) and aged greater than or equal to (>=) 18 years.
  • Must have a histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
  • Must have documented metastatic hormone-sensitive prostate cancer (mHSPC)
  • Must have agreed with the treating physician to initiate treatment with apalutamide (plus androgen-deprivation therapy [ADT]) in accordance with the current product characteristics summary, based on the physician's decision, prior to study inclusion
  • Able to understand the content of the patient information sheet and has provided oral consent for data collection. Has received the information sheet and has not objected to data collection
  • Must have a baseline prostate-specific antigen (PSA) level collected prior to the first administration of apalutamide.
  • Must agree to complete adherence and quality-of-life questionnaires during the study, including before the first administration of apalutamide

Exclusion criteria:

  • Has already received or is currently receiving apalutamide, or any other androgen receptor pathway inhibitor (ARPI; including but not limited to abiraterone acetate, darolutamide, and enzalutamide) or chemotherapy for mHSPC
  • Has received an investigational drug (including vaccines) or used an invasive investigational medical device within 90 days prior to study start or data collection
  • Is currently receiving active treatment for prostate cancer as part of an interventional study
  • Has received ADT for mHSPC for more than 4 months prior to starting apalutamide treatment
  • Has experienced progression under ADT (and thus became castration-resistant) before starting apalutamide treatment
  • Beneficiary of State Medical Aid [AME]
  • Does not speak/read French
  • Under guardianship or curatorship
  • Under judicial protection

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Metastatic hormone-sensitive prostate cancer (mHSPC): Routine Clinical Practice Setting

Participants with confirmed diagnosis of mHSPC will be enrolled at the time of initiation of treatment with apalutamide (Month 0) in routine clinical practice and will be followed up until 12 months after end of study visit (Month 12). No intervention will be administered as a part of this study.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants With Adherence to Apalutamide at 12 Months
大体时间:At 12 months

Adherent participants are defined as participants adherent to apalutamide at every visit until 12 months according to the Medication Adherence Report Scale (MARS-5). MARS-5 is a well-known participant-reported adherence measure (PRAM) consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 12 months
Number of Participants Reporting Change in Adherence According to MARS-5 by Apalutamide Formulation
大体时间:At 12 months

Participants with changes in adherence according to the MARS-5, by apalutamide formulation will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 12 months

次要结果测量

结果测量
措施说明
大体时间
Clinical Risk Factor Among Adherent and Non-adherent Participants: ECOG Status
大体时间:Up to 12 months

Clinical risk factors for treatment the Eastern Cooperative Oncology Group (ECOG) will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Comorbidities
大体时间:Up to 12 months

Clinical risk factors for treatment prostate comorbidities will be reported.

Up to 12 months
Clinical Factors of Adherence at 12 Months: Disease Volume
大体时间:At 12 months

Predictive clinical factors of adherence that is disease volume at 12 months will be reported.

At 12 months
Percentage of Adherent Participants at 3, 6, and 9 Months
大体时间:At 3,6,9 months

Percentage of adherent participants at 3 months, 6 months and 9 months according to the MARS-5 will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication. Participants are asked to evaluate how often they adopt each behavior with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 3,6,9 months
Number of Participants Reporting Change in Adherence According to MARS-5 by Apalutamide Formulation at 3, 6 and 9 Months
大体时间:At 3, 6 and 9 months

Participants with changes in adherence according to the MARS-5, by apalutamide formulation will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 3, 6 and 9 months
Number of Participants with Risk of Non-Adherence as per Social, Psychological, Usage and Rational (SPUR) Factors as per SPUR Adherence Tool
大体时间:Baseline, Months 3, 6, 9 and 12

SPUR is a validated, participant-reported questionnaire that assesses adherence-related behavior across thirteen specific behavioral drivers categorized into four dimensions: Social, Psychological, Usage, and Rational. It consists of 24 items and uses a 5-point Likert scale for each item (ranging from "strongly disagree" to "strongly agree"), with some items reverse-coded to minimize response bias. Scores are calculated for each behavioral driver dimension and score indicating the risk of non-adherence is calculated from them, allowing assessment of global non-adherence risk as well as analysis of the behavioral constituents of that risk by considering the mix of drivers present and their relative importance. Here, higher scores indicate more adherence.

Baseline, Months 3, 6, 9 and 12
Spearman Correlation Coefficients at Baseline and Month 12
大体时间:At Baseline and Month 12

Spearman correlation coefficients between each of the 13 behavioral drivers will be reported.

At Baseline and Month 12
SPUR Global Risk Score at Baseline and Month 12
大体时间:At Baseline and Month 12

SPUR is a validated, participant-reported questionnaire that assesses adherence-related behavior across thirteen specific behavioral drivers categorized into four dimensions: Social, Psychological, Usage, and Rational. It consists of 24 items and uses a 5-point Likert scale for each item (ranging from "strongly disagree" to "strongly agree"), with some items reverse-coded to minimize response bias. Scores are calculated for each behavioral driver dimension and score indicating the risk of non-adherence is calculated from them, allowing assessment of global non-adherence risk as well as analysis of the behavioral constituents of that risk by considering the mix of drivers present and their relative importance. Here, higher scores indicate more adherence.

At Baseline and Month 12
Functional Assessment of Cancer Therapy- Prostate (FACT-P) Score
大体时间:At Baseline, Months 3, 6, 9, 12

The FACT-P questionnaire is used to assess quality of life (QoL) in men undergoing therapy for prostate cancer. It is composed of 39 items using a 5-point Likert-like scale. Each item is rated on a 0 to 4, and then combined to produce subscale scores, as well as a global QoL score. Higher scores represent better QoL.

At Baseline, Months 3, 6, 9, 12
Change from Baseline in FACT-P Score at 3, 6 and 9 Months
大体时间:Baseline, Months 3, 6, 9, 12

The FACT-P questionnaire is used to assess quality of life in men undergoing therapy for prostate cancer. It is composed of 39 items using a 5-point Likert-like scale. Each item is rated on a 0 to 4 , and then combined to produce subscale scores, as well as a global QoL score. Higher scores represent better QoL.

Baseline, Months 3, 6, 9, 12
Demographics Characteristics of Participants: Age
大体时间:Baseline

The demographic characteristics of participants that is, age will be reported.

Baseline
Demographics Characteristics of Participants: Socio-Professional Category
大体时间:Baseline

The demographic characteristics of participants that is, socio-professional category (the participant's last occupation held prior to retirement: Managerial [higher managerial or lower managerial], Non-managerial [intermediate or small employers or lower supervisory or semi-routine or routine], Never worked or long-term unemployed will be reported.

Baseline
Demographics Characteristics of Participants: G8 Geriatric Screening Score
大体时间:Baseline

The demographic characteristics of participants that is, G8 geriatric screening score will be reported. The G8 consists of eight items: participant age (greater than [>]85, 80-85, less than [<]80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with higher scores indicating a lower risk of impairments.

Baseline
Prostate-Specific Antigen (PSA) Level at Androgen-Deprivation Therapy (ADT) Initiation
大体时间:Up to 12 months

PSA levels at ADT initiation will be reported.

Up to 12 months
PSA Level at Baseline
大体时间:At Baseline

PSA levels at baseline will be reported.

At Baseline
Change from Baseline in PSA Levels
大体时间:Baseline up to 12 months

Change from baseline in PSA levels will be reported.

Baseline up to 12 months
Serum Testosterone at Baseline
大体时间:At baseline

Serum testosterone levels will be reported.

At baseline
Time from Initial Diagnosis of Prostate Cancer to Metastatic Stage
大体时间:Baseline up to 12 months

Time from initial diagnosis of prostate cancer to metastatic stage for metachronous participants will be reported.

Baseline up to 12 months
Type of Imaging Methods Used for Cancer Diagnostics
大体时间:Baseline

Number of participants with different type of imaging methods used for cancer diagnostic (for example, magnetic resonance imaging [MRI], Prostate Specific Membrane Antigen Positron Emission Tomography [PSMA-PET], Positron emission tomography [PET] choline, Computed Tomography scan [CT scan], bone scan) will be reported.

Baseline
Osteodensitometry Score
大体时间:Baseline

Osteodensitometry score, a type of imaging method used for cancer diagnostic will be reported.

Baseline
Tumor assessment: Location of Metastases
大体时间:Baseline

Location of metastases as assessed by bone and CT/MRI scans, PSMA-PET scans and any other imaging methods documented in routine practice will be recorded.

Baseline
Tumor assessment: Number of Lesions
大体时间:Baseline

Number of lesions as assessed by bone and CT/MRI scans, PSMA-PET scans and any other imaging methods documented in routine practice will be recorded.

Baseline
ECOG Performance Status
大体时间:At Baseline

ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead.

At Baseline
Number of Participants with History of Treatment for Prostate Cancer
大体时间:Baseline

Participants with history of treatment for prostate cancer will be reported.

Baseline
Number of Participants Reporting Concomitant Diseases
大体时间:Baseline

Participants with Current concomitant diseases (co-morbidities) will be reported.

Baseline
Number of Participants With Vital Sign Assessments
大体时间:Baseline

Participants with relevant vital sign assessment (blood pressure and pulse) will be reported.

Baseline
Time from Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Diagnosis to Treatment Initiation
大体时间:Baseline up to 12 months

Time from mHSPC diagnosis to treatment initiation is defined as the time between date of mHSPC diagnosis and first administration of apalutamide.

Baseline up to 12 months
Percentage of Participants Reaching Undetectable PSA
大体时间:At Months 3,6,9,12

Percentage of participants with undetectable PSA levels that is PSA level less than or equal to (<=) 0.2 nanogram per milliliter (ng/mL) will be reported.

At Months 3,6,9,12
Percentage of Participants Reaching Ultralow (UL) PSA
大体时间:At Months 3,6,9,12

Percentage of participants with ultralow PSA levels that is PSA level <= 0.02 ng/mL will be reported.

At Months 3,6,9,12
Time to Undetectable PSA
大体时间:Up to 12 months

Time to undetectable PSA is defined as the time between first administration of apalutamide and date of undetectable PSA.

Up to 12 months
Time to UL PSA
大体时间:Up to 12 months

Time to UL PSA is defined as the time between first administration of apalutamide and date of UL PSA.

Up to 12 months
Number of Participants with Greater Than or Equal to (>=) 50% Decline in PSA Values (PSA 50) from Baseline
大体时间:Baseline up to 12 months

Participants with >=50% reduction in PSA value from baseline will be reported.

Baseline up to 12 months
Number of Participants with >= 90% Decline in PSA Values (PSA 90) from Baseline
大体时间:Baseline up to 12 months

Participants with >=90% reduction in PSA value from baseline will be reported.

Baseline up to 12 months
Number of Participants with Decrease in PSA Levels (PSA Halving-time)
大体时间:Up to 12 months

Participants with decrease in PSA levels (PSA halving-time) over time will be reported.

Up to 12 months
Progression-Free Survival (PFS)
大体时间:At Months 3,6,9,12

PFS is defined as the time from initiation of apalutamide until earliest record of disease progression determined by physician's assessment, or death.

At Months 3,6,9,12
Number of Deaths
大体时间:At Months 3,6,9,12

The number of deaths at months 3,6,9 and 12 will be reported.

At Months 3,6,9,12
Number of Participants Reporting Change Since Baseline in Apalutamide and ADT Modalities
大体时间:At Baseline, Months 3,6,9,12

Participants reporting changes since baseline in Apalutamide and ADT Modalities (that is, dose, route of administration, number of tablets, time of intake) will be reported.

At Baseline, Months 3,6,9,12
Time from mHSPC Diagnosis to ADT Treatment Initiation
大体时间:Baseline up to Month 12

Time from mHSPC diagnosis to ADT treatment initiation will be reported.

Baseline up to Month 12
Time Between ADT and Apalutamide Treatment Initiation
大体时间:Baseline up to Month 12

Time between ADT and apalutamide initiation will be reported.

Baseline up to Month 12
Number of Participants with Apalutamide Treatment Discontinuation
大体时间:At Months 3,6,9,12

Participants who have discontinued apalutamide treatment will be reported.

At Months 3,6,9,12
Reasons for Discontinuation of Apalutamide Treatment
大体时间:At Months 3,6,9,12

Participants who have discontinued apalutamide treatment and the reasons for discontinuation will be reported.

At Months 3,6,9,12
Time to Discontinuation of Apalutamide Treatment
大体时间:At Months 3,6,9,12

Time to discontinuation of apalutamide treatment will be reported.

At Months 3,6,9,12
Number of Participants Receiving Planned Subsequent Treatment for Prostate Cancer
大体时间:At Months 3,6,9,12

Participants receiving planned subsequent treatment for prostate cancer will be reported.

At Months 3,6,9,12
Percentage of Participants who Consulted for Treatment
大体时间:At Months 3,6,9,12

The percentage of participants who consulted for treatment will be reported.

At Months 3,6,9,12
Percentage of Participants who Used Caregiver Support
大体时间:At Months 3,6,9,12

Percentage of participants who use caregiver support will be reported.

At Months 3,6,9,12
Number of Participants Receiving Concomitant Treatments
大体时间:At Baseline, Months 3,6,9,12

Participants receiving concomitant treatments will be reported.

At Baseline, Months 3,6,9,12
Number of Participants with a Change in Concomitant Treatments
大体时间:At Months 3,6,9,12

Participants with a change in concomitant treatments will be reported.

At Months 3,6,9,12
Number of Participants Experiencing At Least One Adverse Event (AE)
大体时间:At Months 3,6,9,12

An adverse event is any untoward medical occurrence in a participant administered a medicinal product. An adverse event does not necessarily have a causal relationship with the treatment. A serious adverse event is any untoward medical occurrence that at any dose: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is a suspected transmission of any infectious agent via a medicinal product or is medically important. Severity of AEs will be graded as follows: Mild (Easily tolerated symptoms), Moderate (Sufficient discomfort, causes interference with normal activity) and Severe (Extreme distress).

At Months 3,6,9,12
Percentage of Undetectable PSA According to Adherence Levels
大体时间:At Months 3,6,9,12

Percentage of undetectable PSA according to adherence levels, that is PSA level <= 0.2 ng/mL will be reported.

At Months 3,6,9,12
Percentage of UL PSA According to Adherence Levels
大体时间:At Months 3,6,9,12

Percentage of UL PSA according to adherence levels, that is PSA level <= 0.02 ng/mL will be reported.

At Months 3,6,9,12
Number of Participants with PSA 50 Response According to Adherence Levels
大体时间:At Months 3,6,9, and 12

Participants with >=50% reduction in PSA value from baseline according to adherence levels will be reported.

At Months 3,6,9, and 12
Number of Participants with PSA 90 Response According to Adherence Levels
大体时间:At Months 3,6,9, and 12

Participants with >=90% reduction in PSA value from baseline according to adherence levels will be reported.

At Months 3,6,9, and 12
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Use of Concomitant Treatments
大体时间:Up to 12 months

Participants using the concomitant treatments will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Prostate Specific Antigen (PSA) Rate
大体时间:Up to 12 months

Clinical risk factors for prostate specific antigen (PSA) rate will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Socio-professional Category
大体时间:Up to 12 months

Participants with socio-professional category will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Use of Disease Specialized Consultations
大体时间:Up to 12 months

Participants reporting the use of disease specialized consultations will be reported.

Up to 12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Janssen-Cilag France Clinical Trial、Janssen-Cilag France

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月18日

初级完成 (估计的)

2028年1月3日

研究完成 (估计的)

2028年9月18日

研究注册日期

首次提交

2026年1月26日

首先提交符合 QC 标准的

2026年3月4日

首次发布 (实际的)

2026年3月5日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅